Twenty-two patients with genetically verified LGMD2A (age 37 ± 14 years) participated in this study described in (Table 1) and also in two previous studies. [24,25] All investigations were ...

Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist, in post-bariatric hypoglycemia underway; completion of recruitment expected in 2025, with topline ...

Our fourth clinical program is evaluating AMX0114 for the treatment of ALS. AMX0114 is an antisense oligonucleotide that ...

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

Excessive elevation of intracellular calcium and uncontrolled activation of calcium-sensitive events are believed to play a central role in ischemic neuronal damage. Calcium-activated proteolysis by ...

Mutations in the dysferlin gene lead to limb girdle muscular dystrophy 2B, Miyoshi myopathy and distal anterior compartment myopathy. A cohort of 36 patients affected by dysferlinopathy is described, ...

Sometimes your mattress needs upgrading through no fault of it's own, but rather because you have aged out of your current bed. Even the best mattresses you can buy this year won't live forever ...

Android 5.1.1, up to 6.0.1, MIUI 9.5 ...